$25.95
-0.37[-1.41%]
At close: Apr 19
$25.95
0[0.00%]
After Hours: 4:15PM EDT
Arcturus Therapeutics
(NASDAQ:ARCT)Arcturus Therapeutics Stock (NASDAQ:ARCT), Analyst Ratings, Price Targets, Predictions
Arcturus Therapeutics Holdings Inc has a consensus price target of $44.21, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on March 20, 2024, March 11, 2024, and March 8, 2024. With an average price target of $69 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 165.90% upside for Arcturus Therapeutics Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
HC Wainwright & Co.
Wells Fargo
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Arcturus Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/20/2024 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 131.21% | HC Wainwright & Co. | — | → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2024 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 235.26% | Canaccord Genuity | Whitney Ijem | $81 → $87 | Maintains | Buy | Get Alert |
| 03/08/2024 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 131.21% | HC Wainwright & Co. | Ed Arce | → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 123.51% | Wells Fargo | John Abbott | $45 → $58 | Maintains | Overweight | Get Alert |
| 02/08/2024 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 84.97% | Citigroup | Yigal Nochomovitz | $40 → $48 | Maintains | Buy | Get Alert |
| 12/13/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | — | Canaccord Genuity | Whitney Ijem | — | Initiates | → Buy | Get Alert |
| 11/28/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 108.09% | Cantor Fitzgerald | Pete Stavropoulos | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 173.6% | William Blair | Myles Minter | → $71 | Initiates | → Outperform | Get Alert |
| 07/14/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | — | Guggenheim | Seamus Fernandez | — | Maintains | Buy | Get Alert |
| 07/14/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | Buy → Buy | Get Alert |
| 07/14/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 108.09% | Cantor Fitzgerald | Pete Stavropoulos | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 06/01/2023 | ARCT | Buy Now | Arcturus Therapeutics | $25.95 | 96.53% | HC Wainwright & Co. | Ed Arce | → $51 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Arcturus Therapeutics (ARCT)?
The latest price target for Arcturus Therapeutics (NASDAQ: ARCT) was reported by HC Wainwright & Co. on March 20, 2024. The analyst firm set a price target for $60.00 expecting ARCT to rise to within 12 months (a possible 131.21% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcturus Therapeutics (ARCT)?
The latest analyst rating for Arcturus Therapeutics (NASDAQ: ARCT) was provided by HC Wainwright & Co., and Arcturus Therapeutics reiterated their buy rating.
When was the last upgrade for Arcturus Therapeutics (ARCT)?
The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.
When was the last downgrade for Arcturus Therapeutics (ARCT)?
The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.
When is the next analyst rating going to be posted or updated for Arcturus Therapeutics (ARCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on March 20, 2024 so you should expect the next rating to be made available sometime around March 20, 2025.
Is the Analyst Rating Arcturus Therapeutics (ARCT) correct?
While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a reiterated with a price target of $0.00 to $60.00. The current price Arcturus Therapeutics (ARCT) is trading at is $25.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.